Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2018 | Alvocidib plus cytarabine and mitoxantrone in MCL1-dependent R/R AML

Tara Lin • 18 Jan 2019
ASH 2018
Acute Myeloid Leukemia Leukemia Alvocidib Cytarabine Mitoxantrone
Zella 201

In this interview, Tara Lin, MD, of the University of Kansas Medical Center, Kansas City, KS, discusses the results of the Phase II Zella 201 study (NCT02520011) evaluating the clinical response of alvocidib in combination with cytarabine and mitoxantrone (ACM) in MCL1-dependent, relapsed/refractory acute myeloid leukemia (AML) patients. Speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Dr Lin discusses the clinical activity, particularly in those refractory to frontline therapy, of alvocidib given prior to cytarabine and mitoxantrone in MCL1-dependent AML.

More from Tara Lin

3:06
Improved understanding of CPX-351 in AML: impact of HCT & final EAP results
Tara Lin • 18 Jan 2019

Related Videos

1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals